Cargando…
Metastatic Merkel cell carcinoma response to nivolumab
BACKGROUND: Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine malignancy with limited treatment options. Several lines of evidence support the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis as a likely contributor to immune evasion in MCC. CASE PRESENTATION: We re...
Autores principales: | Walocko, Frances M., Scheier, Benjamin Y., Harms, Paul W., Fecher, Leslie A., Lao, Christopher D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109712/ https://www.ncbi.nlm.nih.gov/pubmed/27879975 http://dx.doi.org/10.1186/s40425-016-0186-1 |
Ejemplares similares
-
Erratum to: Metastatic Merkel cell carcinoma response to nivolumab
por: Walocko, Frances M., et al.
Publicado: (2017) -
Unknown primary Merkel cell carcinoma in the immunosuppressed patient: Case series
por: Rizzo, Jason M., et al.
Publicado: (2020) -
Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021) -
Merkel cell carcinoma metastatic to the small bowel mesentery
por: Matkowskyj, Kristina A., et al.
Publicado: (2011) -
Challenges of New Approaches in Metastatic Merkel Cell Carcinoma
por: Monteiro, Ana, et al.
Publicado: (2020)